Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110282 | 0.82 | HTT (0.50) | FFAR1NSD2ALDH1A1CYP19A1 | |
| SCHEMBL5779411 | 0.79 | NSD2 (0.41) | NSD2MAP2K1 | |
| SCHEMBL1953084 | 0.77 | PYCR1 (0.54) | RIPK1KDM4EALDH1A1 | |
| SCHEMBL29810587 | 0.76 | FFAR1 (0.53) | FFAR1FFAR4TSPODRD3 | |
| SCHEMBL5315954 | 0.76 | FFAR1 (0.53) | FFAR1FFAR4TSPODRD3 | |
| SCHEMBL5118098 | 0.76 | NSD2 (0.63) | NSD2 | |
| SCHEMBL1642300 | 0.76 | FFAR1 (0.48) | FFAR1FFAR4 | |
| SCHEMBL32669543 | 0.75 | FFAR1 (0.37) | FFAR1FFAR4NSD2RIPK1ALDH1A1 | |
| SCHEMBL27001694 | 0.74 | FFAR1 (0.44) | FFAR1FFAR4PSEN1PSEN2APH1B | |
| SCHEMBL5846315 | 0.74 | FFAR1 (0.41) | FFAR1FFAR4RIPK1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | FFAR1 390/4885FFAR4 622/4885NSD2 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.